Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by 18F-FP-(+)-DTBZ PET

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Lin, Kun Ju ^a,b,c   Weng, Yi Hsin ^b,c,d   Hsieh, Chia Ju ^a,b   Lin, Wey Yil ^c   Wey, Shiaw Pyng ^a,b   Kung, Mei Ping ^a,b,e   Yen, Tzu Chen ^c   Lu, Chin Song ^b,c,d   Hsiao, Ing Tsung ^a,b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 FLUOROPROPYLDIHYDROTETRABENZAZINE F 18; TRACER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGE; AGED; AGING; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; IN VIVO STUDY; MALE; NEOCORTEX; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEUS ACCUMBENS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; RAPHE NUCLEUS; SUBCORTEX; SUBSTANTIA NIGRA;

FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROIMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; STATISTICS, NONPARAMETRIC; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84884800413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075952     Document Type: Article

References (38)

1. Fahn S, Libsch L, Cutler R, (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 14: 427-455.
2. Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, et al. (1998) Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C] dihydrotetrabenazine and positron emission tomography. Ann Neurol 44: 326-333.
3. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, et al. (2006) Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 33: 685-694.
4. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, et al. (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med 51: 223-228.
5. Lin KJ, Lin WY, Hsieh CJ, Weng YH, Wey SP, et al. (2011) Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol.
6. Lin KJ, Weng YH, Wey SP, Hsiao I, Lu CS, et al. (2010) Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med 51: 1480-1485.
7. Braak H, Rüb U, Gai W, Del Tredici K, (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536.
8. Litvan I, Paulsen JS, Mega MS, Cummings JL, (1998) Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 55: 1313.
9. Hirano S, Shinotoh H, Eidelberg D, (2012) Functional brain imaging of cognitive dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 83: 963-969.
10. Siderowf A, Lang AE, (2012) Premotor Parkinson's disease: Concepts and definitions. Movement Disorders 27: 608-616.
11. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M, (2008) Quality of life in Parkinson's disease: the relative importance of the symptoms. Movement Disorders 23: 1428-1434.
12. Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, et al. (2011) Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 31: 2065-2075.
13. Tong J, Hornykiewicz O, Furukawa Y, Kish SJ, (2007) Marked dissociation between high noradrenaline versus low noradrenaline transporter levels in human nucleus accumbens. J Neurochem 102: 1691-1702.
14. Sun J, Xu J, Cairns NJ, Perlmutter JS, Mach RH, (2012) Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain. PLOS ONE 7: e49483.
15. Tsao HH, Lin KJ, Juang JH, Skovronsky DM, Yen TC, et al. (2010) Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol 37: 413-419.
16. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J, (1995) A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 2: 89-101.
17. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
18. Oh M, Kim JS, Kim JY, Shin KH, Park SH, et al. (2012) Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 53: 399-406.
19. Scherman D, Raisman R, Ploska A, Agid Y, (1988) [3H] Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain. J Neurochem 50: 1131-1136.
20. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR, (1999) Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C] Dihydrotetrabenazine. J Cereb Blood Flow Metab 19: 1376-1384.
21. Brooks DJ, Piccini P, (2006) Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiat 59: 908.
22. Koeppe R, Frey K, Vander Borght T, Karlamangla A, Jewett D, et al. (1996) Kinetic evaluation of [11C] dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16: 1288-1299.
23. Henry JP, Scherman D, (1989) Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochemical pharmacology 38: 2395-2404.
24. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, et al. (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 50: 348-355.
25. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
26. Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, et al. (2004) Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 45: 393-401.
27. Chan G, Holden JE, Stoessl AJ, Samii A, Doudet DJ, et al. (1999) Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40: 283.
28. Kilbourn MR, DaSilva JN, Frey KA, Koeppe RA, Kuhl DE, (1993) In vivo imaging of vesicular monoamine transporters in human brain using [11C] tetrabenazine and positron emission tomography. J Neurochem 60: 2315-2318.
29. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, et al. (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87: 574-585.
30. Troiano AR, Schulzer M, Fuente-Fernandez RL, Mak E, Mckenzie J, et al. (2010) Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. Synapse 64: 146-151.
31. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, et al. (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26: 1198-1212.
32. Volkow N, Fowler J, Wang G, Logan J, Schlyer D, et al. (1994) Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 36: 237-239.
33. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G, (2001) Differential diagnosis of Parkinson's disease and vascular parkinsonism by 99mTc-TRODAT-1. J Nucl Med 42: 408-413.
34. Innis RB, van Dyck CH, Seibyl JP, Malison RT, Laruelle M, et al. (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. AM J Geriat Psychiat 10: 36-43.
35. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, et al. (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of neurology 40: 873-884.
36. Kim JK, Ahn JH, Park T, Ahn HJ, Kim CS, et al. (2002) Virtual cystoscopy of the contrast material-filled bladder in patients with gross hematuria. AM J Roentgenol 179: 763-768.
37. Villablanca JP, Jahan R, Hooshi P, Lim S, Duckwiler G, et al. (2002) Detection and characterization of very small cerebral aneurysms by using 2D and 3D helical CT angiography. AM J Neuroradiol 23: 1187-1198.
38. Kim J, Cai W, Eberl S, Feng D, (2007) Real-time volume rendering visualization of dual-modality PET/CT images with interactive fuzzy thresholding segmentation. IEEE T Inf Technol B 11: 161-169.